Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Princess Margaret Hospital and University of Toronto, Canada

ESMO 33

12 - 16 Sep 2008

Published: 28 Nov 2008

Views: 15649

Rating:

Save

Prof. Ian Tannock

Sunitinib vs. interferon-alfa as first-line treatment for metastatic renal cancer, from ESMO 2008

Categories:
Prostate & urology

Related Videos

Darolutamide, androgen-deprivation therapy and docetaxel demonstrate promising...

Prof Bertrand Tombal - Université Catholique de Louvain, Brussels, Belgium

Darolutamide, androgen-deprivation therapy and docetaxel demonstrate promising efficacy mHSPC ( Prof Bertrand Tombal - Université Catholique de Louvain, Brussels, Belgium )

Urinary markers in the surveillance setting of non-muscle invasive bladder...

Dr Thomas Dreyer - Aarhus University Hospital, Aarhus, Denmark

Urinary markers in the surveillance setting of non-muscle invasive bladder cancer ( Dr Thomas Dreyer - Aarhus University Hospital, Aarhus, Denmark )

Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective...

Dr Chiara Mercinelli - San Raffaele Scientific Institute, Milan, Italy

Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective perioperative strategy for MIBC ( Dr Chiara Mercinelli - San Raffaele Scientific Institute, Milan, Italy )

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

To test or not to test? Targeted therapies in GU Cancers – leveraging new...

Prof Eva Compérat, Dr Friederike Schlürmann and Dr Guilhem Roubaud

To test or not to test? Targeted therapies in GU Cancers – leveraging new advances in clinical care ( Prof Eva Compérat, Dr Friederike Schlürmann and Dr Guilhem Roubaud )

Pembrolizumab a promising option for MIUC patients after radical surgery

Dr Andrea Apolo - National Cancer Institute, Bethesda, USA

Pembrolizumab a promising option for MIUC patients after radical surgery ( Dr Andrea Apolo - National Cancer Institute, Bethesda, USA )

ASCO GU 2024: Current best practice for mRCC

Prof Jens Bedke, Prof Thomas Powles, Prof Michael Staehler and Dr Wenxin Xu

ASCO GU 2024: Current best practice for mRCC ( Prof Jens Bedke, Prof Thomas Powles, Prof Michael Staehler and Dr Wenxin Xu )

ASCO GU 2024: Latest in PARP inhibitors for prostate cancer

Dr Friederike Schlurmann, Dr Nabil Adra, Dr Emmanuel Antonarakis and Dr Hiroshi...

ASCO GU 2024: Latest in PARP inhibitors for prostate cancer ( Dr Friederike Schlurmann, Dr Nabil Adra, Dr Emmanuel Antonarakis and Dr Hiroshi Kitamura )

More from ecancer